Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

Bone Marrow Transplantation
Paolo AnderliniRichard E Champlin

Abstract

A total of 40 patients with relapsed/refractory Hodgkin's disease (HD) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA-identical sibling (n=20) or a matched unrelated donor (n=20). The median age was 31 years (range 18-58). Disease status at allo-SCT was refractory relapse (n=14) or sensitive relapse (n=26). The conditioning regimens were fludarabine-cyclophosphamide+/-antithymocyte globulin (n=14), a less intensive regimen, and fludarabine-melphalan (FM) (n=26), a more intensive one. The two groups had similar prognostic factors. The median time to neutrophil recovery (ie absolute neutrophil count >/=500/microl) was 12 days (range 10-24). The median time to platelet recovery (ie platelet count >/=20 000/microl) was 17 days (range 7-132). Day 100 and cumulative (18-month) transplant-related mortalities (TRMs) were 5 and 22%. Twenty-four patients (60%) are alive (14 in complete remission or complete remission, unconfirmed/uncertain) with a median follow-up of 13 months (4-78). In all, 16 patients expired (TRM n=8, disease progression n=8). FM patients had better overall survival (73 vs 39% at 18 months; P=0.03), and a trend towards better progression-free survival (37 vs...Continue Reading

References

Mar 5, 1992·The New England Journal of Medicine·W J Urba, D L Longo
Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J E AndersonJ E Sanders
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L GajewskiM M Horowitz
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MilpiedAnthony H Goldstone
Nov 30, 1999·Hematology/oncology Clinics of North America·Richard E ChamplinSergio Giralt
Dec 22, 1999·British Journal of Haematology·David C Linch, Anthony H Goldstone
Jul 25, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·L J Johnston, S J Horning
May 15, 2001·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·D L PorterJoseph H Antin
Dec 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G AkpekR J Jones
Jan 30, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·John R Wingard, Helen Leather

Citations

Jan 25, 2008·Current Treatment Options in Oncology·Kevin A DavidAndrew M Evens
Aug 24, 2010·Current Hematologic Malignancy Reports·Rachel B SalitSteven Z Pavletic
Oct 20, 2012·Current Opinion in Oncology·Anna SuredaLymphoma Working Party of the European Group for Blood and Marrow Transplantation
Jun 22, 2006·International Journal of Hematology·Alana A Kennedy-NasserCliona M Rooney
Aug 15, 2009·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Olivera TarabarSlobodan Marjanović
Nov 22, 2012·Mediterranean Journal of Hematology and Infectious Diseases·Angelo M Carella
Apr 23, 2014·Current Treatment Options in Oncology·Anna SuredaLymphoma Working Party of the European Group for Stem Cell Transplantation
Dec 3, 2014·Hematology/oncology Clinics of North America·Nishitha M Reddy, Miguel-Angel Perales
Oct 1, 2008·Expert Review of Hematology·Dennis A EichenauerGerman Hodgkin Study Group
Jun 1, 2009·Expert Review of Hematology·David Sibon, Pauline Brice
Apr 17, 2013·Expert Opinion on Biological Therapy·Tiziana MoscatoMassimo Martino
Dec 15, 2015·Expert Opinion on Biological Therapy·Massimo MartinoBenedetto Bruno
Nov 30, 2013·Hematology/oncology Clinics of North America·Mark Hertzberg
Oct 3, 2007·Hematology/oncology Clinics of North America·Anna Sureda
Oct 9, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S S TanW E Fibbe
Aug 25, 2007·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Matthew Seftel, Morel Rubinger
Aug 9, 2007·Blood Reviews·Amanda F Cashen, Nancy L Bartlett
Apr 24, 2007·Best Practice & Research. Clinical Haematology·Aristeidis ChaidosJane F Apperley
Aug 20, 2008·British Journal of Haematology·Karl PeggsAnna Sureda
Feb 19, 2008·British Journal of Haematology·Pauline Brice
Mar 17, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Miguel-Angel PeralesPaul A Carpenter
Oct 29, 2010·Advances in Hematology·Evgeny KlyuchnikovAxel Rolf Zander
Jul 16, 2008·Radiologic Clinics of North America·Matthew J Matasar, Andrew D Zelenetz
Aug 8, 2012·Critical Reviews in Oncology/hematology·Paolo G GobbiAlessandro Levis
Jan 31, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Iván AlvarezJorge Sierra
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Esa Jantunen, Anna Sureda
Jun 2, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paolo Anderlini, Richard E Champlin
Mar 18, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Philippe ArmandEdwin P Alyea
Mar 17, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Luca CastagnaArmando Santoro
Jan 13, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marcel P DevettenPaolo Anderlini
Jan 27, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·C G BrunsteinJohn E Wagner
May 20, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·H Joachim Deeg
Jul 22, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sonali M SmithParameswaran Hari
Oct 23, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Lauri M BurroughsDavid G Maloney
Apr 6, 2012·The Korean Journal of Hematology·Erin-Siobhain R Currin, Ajay K Gopal
Mar 15, 2006·Mayo Clinic Proceedings·Stephen M Ansell, James O Armitage
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karl PeggsStephen Mackinnon
Jun 1, 2011·Einstein·Adriano de Moraes ArantesCésar Bariani
Jul 20, 2007·Clinical Pharmacology and Therapeutics·D P Hart, Karl Peggs
Feb 14, 2007·The Oncologist·Brian J Byrne, Jon P Gockerman
Aug 29, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carmen MartínezLymphoma Working Party of the European Group for Blood and Marrow Transplantation
May 24, 2018·Gene Therapy·Kate L LoweGwendolyn Binder
Feb 29, 2020·Therapeutic Advances in Hematology·Theodoros P VassilakopoulosMaria K Angelopoulou

Related Concepts

Graft-vs-Host Disease
Hodgkin Lymphoma, Lymphocyte Depletion
Transplantation, Homologous
Leukocyte Transfusion
Hemopoietic Stem Cell Transplant
Transplantation Conditioning

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.